BioCryst Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:BO1 Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
24 Jun 24	Sell€50,661	Amy McKee	Individual	8,600	€5.89
17 Jun 24	Sell€26,238	A. Sanders	Individual	4,689	€5.60
14 Jun 24	Sell€38,261	Theresa Heggie	Individual	6,698	€5.71
30 May 24	Buy€46,106	Alan Levin	Individual	7,861	€5.87
24 May 24	Buy€14,741	Stephen Aselage	Individual	2,500	€5.90
20 May 24	Buy€86,316	Vincent Milano	Individual	15,000	€5.75
20 May 24	Buy€29,370	Nancy Hutson	Individual	5,000	€5.87
14 May 24	Buy€186,905	Anthony Doyle	Individual	36,300	€5.15
14 May 24	Buy€162,510	Helen Thackray	Individual	30,000	€5.42
13 May 24	Buy€25,618	Alane Barnes	Individual	5,000	€5.12
13 May 24	Buy€152,039	Charles Gayer	Individual	30,000	€5.07
13 May 24	Buy€111,597	Steven K. Galson	Individual	21,940	€5.09
13 May 24	Buy€154,262	Jon Stonehouse	Individual	30,000	€5.14

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of BO1?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	2,037,202	0.984%
Hedge Funds	11,865,000	5.73%
General Public	30,079,228	14.5%
Institutions	163,151,141	78.8%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 64.19% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
10.1%	BlackRock, Inc.	20,915,971	€151.7m	4.81%	no data
10%	The Vanguard Group, Inc.	20,730,939	€150.4m	2.09%	no data
5.73%	Avoro Capital Advisors LLC	11,865,000	€86.1m	-5.61%	1.24%
4.39%	Kynam Capital Management, LP	9,085,368	€65.9m	2.93%	5.49%
4.27%	State Street Global Advisors, Inc.	8,849,588	€64.2m	-5.32%	no data
3.93%	Deerfield Management Company, L.P. Series C	8,135,804	€59.0m	0%	1.09%
2.85%	Alkeon Capital Management, LLC	5,894,274	€42.8m	-0.1%	0.3%
2.34%	Geode Capital Management, LLC	4,837,985	€35.1m	2.71%	no data
2.32%	Teachers Insurance and Annuity Association-College Retirement Equities Fund	4,801,454	€34.8m	6.95%	0.01%
1.86%	Rp Management, Llc, Asset Management Arm	3,846,154	€27.9m	0%	13.48%
1.75%	Rock Springs Capital Management LP	3,622,358	€26.3m	0.09%	0.93%
1.61%	Fisher Asset Management, LLC	3,338,062	€24.2m	16.9%	0.01%
1.58%	GW&K Investment Management, LLC	3,277,600	€23.8m	-3.73%	0.2%
1.25%	Caligan Partners, LP	2,583,585	€18.7m	-43.8%	6.13%
1.09%	T. Rowe Price Group, Inc.	2,252,749	€16.3m	15.6%	no data
1.05%	Two Sigma Advisers, LP	2,181,012	€15.8m	13.6%	0.04%
1.04%	Rice Hall James & Associates, LLC	2,163,743	€15.7m	4.04%	0.86%
0.96%	FMR LLC	1,987,535	€14.4m	2.33%	no data
0.91%	Charles Schwab Investment Management, Inc.	1,887,994	€13.7m	5.76%	no data
0.9%	Northern Trust Global Investments	1,860,925	€13.5m	6.05%	no data
0.89%	Stifel Asset Management Corp.	1,843,289	€13.4m	-0.02%	0.01%
0.87%	Voloridge Investment Management, LLC	1,792,908	€13.0m	-30.8%	0.05%
0.86%	Columbia Management Investment Advisers, LLC	1,772,501	€12.9m	-4.99%	no data
0.85%	Two Sigma Investments, LP	1,760,808	€12.8m	5.16%	0.03%
0.81%	Goldman Sachs Group, Investment Banking and Securities Investments	1,677,332	€12.2m	-15.5%	0.01%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 06:01
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioCryst Pharmaceuticals, Inc. is covered by 30 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Huidong Wang	Barclays
Tazeen Ahmad	BofA Global Research
Dae Gon Ha	BTIG